Trump’s honeymoon period with the American public has been particularly brief. He appears to be less popular at the 100-day mark than any other president since the inception of approval polling, ...

Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported ...

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

Showcase your company news with guaranteed exposure both in print and online Network with our region's hottest startups! Pittsburgh Inno presents the Startups to Watch event… The Future of Bay ...

Cava CFO’s people-centric approach to company finance, markets hold steady for now, tariffs unlikely to end income tax.